The Evolving Treatment Landscape for Chronic Thromboembolic Pulmonary Hypertension (CTEPH): A Review for Specialty Pharmacists

This activity was originally broadcast live at the 2022 Asembia Specialty Pharmacy Summit.

Program Description

Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare, progressive disease that is frequently misdiagnosed due to under recognition among health care professionals. With specific knowledge about symptoms and comorbidities associated with CTEPH, pharmacists can be essential in assisting in its identification by referring patients to CTEPH specialists and recommending they receive appropriate screening and diagnostic tests. Until 2013, there were no medications approved specifically for the treatment and management of CTEPH. However, several medication classes are under investigation for use in patients with CTEPH, and pharmacists involved in the treatment and management of these patients must be familiar with safety and efficacy data of these agents, if approved. As medication experts, pharmacists must be familiar with REMS program requirements for adverse effects and drug interactions associated with CTEPH therapies. This program will also review the role of the pharmacist on the multidisciplinary team in providing specific counseling strategies to promote patient adherence to therapy.

Target audience: Specialty pharmacists, health system pharmacists and managed care pharmacists

Type of activity: Application
Release date: September 8, 2022
Expiration date: November 8, 2022

Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine the pathogenesis, prevalence, clinical presentation, risk factors, and impact of chronic thromboembolic pulmonary hypertension (CTEPH) on patient health-related quality of life
• Analyze the efficacy and safety data associated with emerging and available therapies for CTEPH
• Investigate the mechanisms of action, dosing, administration, monitoring parameters, and potential adverse effects of current and emerging CTEPH therapies
• Illustrate the role of the pharmacist in managing patients with CTEPH on a multidisciplinary team

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-22-352-L01-P. The activity is available for CE credit through November 8, 2022.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Faculty

Dustin Fraidenburg, MD, and Christopher Ogurchak, PharmD, MPBA, CSP, have no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Michelle C. Carlson, PharmD; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships with commercial interests to disclose.

An anonymous peer reviewer has been used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

The content of this activity may include information regarding the use of products that may be inconsistent with, or outside the approved labeling for, these products in the United States. Pharmacists should note that the use of these products outside current approved labeling is considered experimental and are advised to consult the prescribing information for these products.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms